News
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
Sermorelin Clinical Trials: What the Studies Show
The 11-man study is real. Its results are narrower than the sales pitch, and later studies add evidence without settling the big claims.
-
STEP 1 Trial Results: What the 14.9% Average Means
The 68-week semaglutide study found 14.9% average weight loss versus 2.4% with placebo. The details show who was studied, who stopped treatment and what happened later.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
TrumpRx GLP-1 Prices: Beyond the Starting Price
Wegovy pills start at $149 and some pen offers at $199. Later fills, strength and eligibility determine the bill that follows.
-
Who Discovered MOTS-c? The 2015 USC Discovery
Changhan Lee, Pinchas Cohen, and their colleagues reported MOTS-c in 2015. Its history runs from an overlooked genetic sequence to human observations and an ongoing question about treatment.
-
BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-
10 Questions to Ask Doctor About Tirzepatide
A tirzepatide visit is mostly about fit: the provider needs a clear picture of medical history, medicines, pregnancy plans, digestion, and upcoming procedures. These ten questions explain what matters and why.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
15 Percent Weight Loss: What the Numbers Show
At 220 pounds, 15 percent is 33 pounds. Trials also measured waist, blood pressure, blood sugar, sleep, pain and physical function—but those group averages are not a personal forecast.
-
Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
Zepbound Prescribing Information, Explained
The current label is revised August 2026. It covers two uses, a weekly dose ladder, two absolute contraindications, the boxed thyroid warning, common stomach side effects, pregnancy, and four delivery formats.
-
Kisspeptin Dose: What Human Studies Actually Used
There is no standard kisspeptin dose to copy from a study. Human trials used different peptide forms, routes, and schedules, so a prescription has to be set for the person and the clinical goal.
-
Does Medicare Cover GLP-1 for Weight Loss? It Can
Some Medicare patients now qualify for a $50 monthly GLP-1 prescription. The Bridge has specific product and health requirements, and compounded prescriptions are outside it.
-
MOTS-c and Retatrutide: No Evidence for a Stack
No published study has tested MOTS-c and retatrutide together. Retatrutide cannot be compounded for patient care, while MOTS-c is a separate prescription discussion with much thinner human evidence.
-
MOTS-c for Weight Loss: Human Evidence Is Thin
Mouse studies are interesting, but no completed randomized trial shows that MOTS-c causes weight loss in people. Human studies so far mostly measure the peptide already in the body.
-
MOTS-c Tablets: No Human Evidence Supports Them
MOTS-c tablets have no published human absorption data. The studies behind the peptide used injected animals or measured the MOTS-c people made themselves.
-
MOTS-c vs Tesamorelin: Not a Fat-Loss Contest
MOTS-c and tesamorelin work through different systems, and their evidence is not comparable. Tesamorelin has large late-stage trials for one narrow HIV-related condition; MOTS-c does not yet have completed human treatment results.
-
CJC-1295 Ipamorelin Oral: No Human Absorption Data
No human study has shown that a swallowed or sublingual CJC-1295/ipamorelin product delivers either peptide reliably. The key human drug-level studies used injections or infusions, not pills or troches.
Page 3 of 18 · 344 articles